BJOG: An International Journal of Obstetrics & Gynaecology最新文献

{"title":"Reduced Fetal Movements Green-Top Guideline No. 57.","authors":"Melissa Whitworth,Margaret Fisher,Alexander Heazell, ","doi":"10.1111/1471-0528.70198","DOIUrl":"https://doi.org/10.1111/1471-0528.70198","url":null,"abstract":"","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147753283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Management of Ovarian Hyperstimulation Syndrome Green-Top Guideline No. 5.","authors":"Haitham Hamoda,Andrew J Drakeley,Kate Brian,Isaac O Evbuomwan,Rajneesh Mathur, ","doi":"10.1111/1471-0528.70195","DOIUrl":"https://doi.org/10.1111/1471-0528.70195","url":null,"abstract":"","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"193 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147667036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Pregnancies Following Assisted Conception (Scientific Impact Paper No. 22, 2026 Third Edition)","authors":"T. El-Toukhy, S. Bhattacharya, V. Akande","doi":"10.1111/1471-0528.70181","DOIUrl":"https://doi.org/10.1111/1471-0528.70181","url":null,"abstract":"Multiple pregnancy is a preventable complication of in vitro fertilisation (IVF). Multiple pregnancies are often the result of a treatment approach that means more than one embryo is placed into the womb during each IVF treatment cycle in the belief that this may increase the chance of a successful pregnancy resulting in a live birth. In reality, this approach has led to a higher rate of IVF multiple pregnancies, ranging between one in three and one in seven pregnancies across many parts of the world, including the UK.","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147681907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk‐Reducing Salpingectomy: An Emerging, Novel Ovarian Cancer Prevention Strategy","authors":"Ketankumar Gajjar, Annika Idahl, Annika Strandel, Ranjit Manchanda","doi":"10.1111/1471-0528.70224","DOIUrl":"https://doi.org/10.1111/1471-0528.70224","url":null,"abstract":"<h2>Data Availability Statement</h2>\u0000<p>No primary data are used in this manuscript. The corresponding author can be contacted for any potential queries.</p>","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The First-Trimester Anomaly Scan: From Earlier Detection to Broader Clinical Impact.","authors":"Paolo Ivo Cavoretto","doi":"10.1111/1471-0528.70228","DOIUrl":"https://doi.org/10.1111/1471-0528.70228","url":null,"abstract":"","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis.","authors":"Piotr Wojciechowski,Klaudia Kolonko,Andromachi Giannopoulou,Beata Smela,Elżbieta Olewinska,Kristina Rosa Bolling,Jenifer Sassarini,Lee P Shulman,Vikram Talaulikar","doi":"10.1111/1471-0528.70213","DOIUrl":"https://doi.org/10.1111/1471-0528.70213","url":null,"abstract":"BACKGROUNDElinzanetant, a novel, dual neurokinin-targeted therapy, has been approved in various geographies for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause.OBJECTIVETo compare the efficacy of elinzanetant with non-hormonal pharmaceutical treatments (nHT) in alleviating VMS.SEARCH STRATEGYA systematic literature review of Medline, Embase, and Cochrane databases identified randomised controlled trials (RCTs) published up to October 2025.SELECTION CRITERIARCTs of nHT in women with moderate-to-severe VMS not induced by medical treatment, reporting week 12 results for VMS frequency and severity, sleep disturbances, and quality of life.DATA COLLECTION AND ANALYSISTreatments were compared using a Bayesian network meta-analysis to obtain mean differences (MD) or odds ratios (OR) with 95% credible intervals.MAIN RESULTSOf 17 included RCTs, three assessed elinzanetant 120 mg, two paroxetine 7.5 mg (PRX), four gabapentin 1200-1800 mg (GABA), three fezolinetant 45 mg (FEZO), and five desvenlafaxine 50-200 mg (DVS). Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: -2.11 [-3.31, -0.92]), DVS (MD: -2.77 to -1.72), and GABA (MD: -2.22 to -2.31). The proportion of patients with ≥ 50% reduction in VMS frequency was significantly greater with elinzanetant than DVS 100 mg (OR:1.52 [1.03, 2.24]) and PRX (OR:2.20 [1.49, 3.28]), and comparable to DVS 150 mg and FEZO. Elinzanetant significantly reduced VMS severity versus DVS 50 mg (MD: -0.37 [-0.56, -0.17]) and was comparable with other assessed treatments. Elinzanetant reduced nighttime awakenings significantly more effectively than PRX (MD: -0.82 [-1.26, -0.39]) and all DVS regimens. Elinzanetant significantly improved sleep disturbance (PROMIS SD-SF-8b) score versus FEZO (MD: -2.67 [-3.92, -1.42]). Change in MENQoL did not differ significantly.CONCLUSIONSIn this indirect comparison, elinzanetant showed superior or comparable efficacy to NKT or nHT in reducing the frequency and severity of VMS, along with improving sleep disturbances, supporting its role in VMS management.","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Declining Episiotomy Rates and OASIS: Association Is Not Causation.","authors":"Melania Maria Amorim,Geyson Marinho,Filipe Pinheiro,Alexandre Delgado","doi":"10.1111/1471-0528.70210","DOIUrl":"https://doi.org/10.1111/1471-0528.70210","url":null,"abstract":"","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147393922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of Women and Clinicians During the Introduction of Uterine Transplantation to the UK: A Qualitative Case Study.","authors":"Daisy Elliott,Richard J Smith,Maeve Coyle,Rhiannon Macefield,Saliha Vali,Anni King,Natalie Blencowe,Cynthia Ochieng,Christin Hoffmann,Isabel Quiroga,Ben P Jones,Ariadne L'Heveder,Kerry N L Avery,Jane M Blazeby","doi":"10.1111/1471-0528.70206","DOIUrl":"https://doi.org/10.1111/1471-0528.70206","url":null,"abstract":"OBJECTIVETo explore the experiences of women and clinicians during the introduction of uterine transplantation (UTx) to the UK.DESIGNA qualitative study utilising prospective case study methodology (interviews and observations) over 6 years.SETTINGIn the UK, five uterine transplants have been completed to date-two using living donors and three using deceased donors. In addition, three deceased donor retrievals were undertaken but did not proceed to implantation.SAMPLEData included 18 audio-recorded consultations with potential recipients and clinicians, 22 interviews with seven clinicians and eight follow-up interviews with women.METHODSData were synthesised using thematic analytical methods.RESULTSThe first theme, 'Emotional and ethical dimensions of UTx decision-making', explores how women and clinicians navigated uncertainty, risk and hope, including dilemmas around living versus deceased donation. The second, 'Building and refining a UK UTx programme', reflects on bridging disciplines, managing initial cases and iteratively improving protocols through teamwork and reflection. The third, 'Living through the unknowns after transplantation', captures recipients' post-operative experiences, their collaboration with clinicians, and uncertainties surrounding recovery, embryo transfer and pregnancy.CONCLUSIONProspective qualitative research enabled surgeons to reflect on their practice while generating insights to optimise uterine transplant delivery in the UK and internationally. Findings offer practical guidance for navigating uncertainty and risk when introducing new procedures and highlight ways to strengthen support for women throughout the process. Overall, this study demonstrates how prospective qualitative methods can provide crucial insights into the technical, ethical and emotional dimensions of innovative procedures like UTx.","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"266 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147393924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions.","authors":"Jiawen Dong,Sarah Hillman,Sharon Dixon,Anupa Shah,Radha Venkatakrishnan,Jeremy W Tomlinson","doi":"10.1111/1471-0528.70214","DOIUrl":"https://doi.org/10.1111/1471-0528.70214","url":null,"abstract":"BACKGROUNDThe transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms, understanding and discussing the cardiometabolic impacts of HRT are necessary to facilitate informed decision-making at treatment initiation and continuation, and to select appropriate regimens.METHODOLOGYA narrative review.RESULTSExisting evidence suggests that HRT is likely to impact the development of metabolic risk factors including visceral fat accumulation, adverse changes in lipid profile, blood pressure and glycaemic control. Findings from randomised controlled trials have refined our understanding of the impact of HRT on cardiometabolic outcomes including coronary heart disease and stroke. Furthermore, recent research has highlighted the impact of the menopause on the development and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) that has been poorly studied in the context of HRT. The route of oestrogen administration, timing of initiation and type of progestogen are all likely to affect the impact of HRT on many of these outcomes. There has recently been extensive media interest in HRT in some countries resulting in increased prescription rates. Understanding the impact of HRT on cardiometabolic risk is therefore particularly important. In this narrative review, we discuss the existing evidence and clinical guidelines on the effect of HRT on cardiometabolic risk factors and the risk of coronary heart disease, stroke and MASLD, highlighting areas of uncertainty and priorities for further research.","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dedicated First-Trimester Anomaly Scan in a National Prenatal Screening Program and Timing of Diagnosis: The Prospective IMITAS Cohort Study.","authors":"Kim Bronsgeest,Eline E R Lust,Lidewij Henneman,Neeltje Crombag,Caterina M Bilardo,Robert-Jan H Galjaard,Esther Sikkel,Nan van Geloven,Audrey B C Coumans,Ayten Elvan-Taşpınar,Sander Galjaard,Attie T J I Go,Elisabeth van Leeuwen,Gwendolyn T R Manten,Eva Pajkrt,Mireille N Bekker,Monique C Haak, ","doi":"10.1111/1471-0528.70192","DOIUrl":"https://doi.org/10.1111/1471-0528.70192","url":null,"abstract":"OBJECTIVETo determine the diagnostic yield of a nationally implemented first-trimester anomaly scan (FTAS), compared to standard obstetric care with a second-trimester anomaly scan.DESIGNProspective observational cohort study.SETTINGNationwide prenatal screening program in the Netherlands.POPULATIONPregnant women referred for suspected fetal anomalies with subsequent abnormal diagnostic scans in 2021-2022.METHODSAll fetal diagnoses < 18 weeks' gestational age (GA) were registered: 8 months before (BEFORE) and 1 year after (AFTER) FTAS implementation. BEFORE-cohort: referrals after routine scans (e.g., dating scans). AFTER-cohort: all referrals, including FTAS. Corrections were made for missing referrals < 12 + 3 weeks in the AFTER-cohort. Time adjustment was made in the BEFORE-cohort. Anomalies were categorised as: First-Trimester Major Anomalies (FTMA), often detectable anomalies and other anomalies.MAIN OUTCOME MEASURESNumber of fetal anomalies, time to final diagnosis, GA at termination of pregnancy (TOP).RESULTSAbnormal diagnostic scans increased from 750 to 1261 (BEFORE vs. AFTER) with definitive diagnoses in 609 vs. 940. Time to diagnosis and GA at TOP in c-BEFORE were comparable to c-AFTER (11 vs. 13 days and GA 14 + 6 vs. 15 + 1, respectively). FTAS increased the detection of often detectable and other anomalies (53 vs. 124 and 248 vs. 474, respectively). FTMA slightly increased (308 vs. 342).CONCLUSIONSFTAS substantially increases detection of fetal anomalies, primarily often detectable and other anomalies. Overall GA at diagnosis or TOP increased marginally, but some cases required an extended period of diagnostic evaluation.","PeriodicalId":8984,"journal":{"name":"BJOG: An International Journal of Obstetrics & Gynaecology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147381353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}